




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 239/56, 401/14, A61K 31/505	A1	(11) International Publication Number: WO 00/10980 (43) International Publication Date: 2 March 2000 (02.03.00)
(21) International Application Number: PCT/EP99/06093 (22) International Filing Date: 18 August 1999 (18.08.99) (30) Priority Data: 9818375.9 21 August 1998 (21.08.98) GB 9902009.1 29 January 1999 (29.01.99) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): LEACH, Colin, Andrew [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). SMITH, Stephen, Allan [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: CONNELL, Anthony, Christopher; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS



(57) Abstract

Pyrimidones of formula (I) are inhibitors of the enzyme LpPLA2 and thereof use in treating inter alia atherosclerosis. In formula (I), R¹ is COOH or a salt thereof, COOR¹⁰, CONR¹¹R¹², CN or CH₂OH; R² is a mono- or bicyclic aromatic ring system or a mono- or bicyclic heteroaromatic ring system; R³ is C₁₋₂₀alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₅alkyl, C₁₋₁₀alkoxyC₁₋₁₀alkyl, or an aromatic or heteroaromatic ring system; W is SO₂ or a bond; X is O or S; and Y is a group of the formula A¹-A²-A³ in which A¹ and A³ each represent a bond or a straight chain or branched alkylene group, said alkylene group(s) containing a total of 1 to 10 carbon atoms and A² represents a bond or O, S, SO, SO₂, CO, C=CH₂, CONH, NHCO, CR¹⁵R¹⁶, CH=CH or C≡C, providing that when A² is O, S, SO, SO₂ or CONH, A³ contains at least two carbon atoms linking the A² group and the CH₂ group in formula (I).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS

The present invention relates to certain novel pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions
5 containing them and their use in therapy, in particular in the treatment of atherosclerosis.

WO 95/00649 (SmithKline Beecham plc) describe the phospholipase A2 enzyme Lipoprotein Associated Phospholipase A₂ (Lp-PLA₂), the sequence, isolation and purification thereof, isolated nucleic acids encoding the enzyme, and recombinant host
10 cells transformed with DNA encoding the enzyme. Suggested therapeutic uses for inhibitors of the enzyme included atherosclerosis, diabetes, rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation. A subsequent publication from the same group further describes this enzyme (Tew D *et al*, Arterioscler Thromb Vas Biol 1996;16;591-9) wherein it is referred to as LDL-PLA₂. A
15 later patent application (WO 95/09921, Icos Corporation) and a related publication in Nature (Tjoelker *et al*, vol 374, 6 April 1995, 549) describe the enzyme PAF-AH which has essentially the same sequence as Lp-PLA₂ and suggest that it may have potential as a therapeutic protein for regulating pathological inflammatory events.

20 It has been shown that Lp-PLA₂ is responsible for the conversion of phosphatidylcholine to lysophosphatidylcholine, during the conversion of low density lipoprotein (LDL) to its oxidised form. The enzyme is known to hydrolyse the sn-2 ester of the oxidised phosphatidylcholine to give lysophosphatidylcholine and an oxidatively modified fatty acid. Both products of Lp-PLA₂ action are biologically active with
25 lysophosphatidylcholine, a component of oxidised LDL, known to be a potent chemoattractant for circulating monocytes. As such, lysophosphatidylcholine is thought play a significant role in atherosclerosis by being responsible for the accumulation of cells loaded with cholesterol ester in the arteries. Inhibition of the Lp-PLA₂ enzyme would therefore be expected to stop the build up of these macrophage enriched lesions
30 (by inhibition of the formation of lysophosphatidylcholine and oxidised free fatty acids) and so be useful in the treatment of atherosclerosis.

The increased lysophosphatidylcholine content of oxidatively modified LDL is also thought to be responsible for the endothelial dysfunction observed in patients with
35 atherosclerosis. Inhibitors of Lp-PLA₂ could therefore prove beneficial in the treatment of this phenomenon. An Lp-PLA₂ inhibitor could also find utility in other disease states that exhibit endothelial dysfunction including diabetes, hypertension, angina pectoris and after ischaemia and reperfusion.

In addition, Lp-PLA₂ inhibitors may also have a general application in any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA₂. Examples of such disorders include psoriasis.

5

Furthermore, Lp-PLA₂ inhibitors may also have a general application in any disorder that involves lipid peroxidation in conjunction with Lp-PLA₂ activity to produce the two injurious products, lysophosphatidylcholine and oxidatively modified fatty acids. Such conditions include the aforementioned conditions atherosclerosis, diabetes, rheumatoid


10 arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation. Further such conditions include various neuropsychiatric disorders such as schizophrenia (see Psychopharmacology Bulletin, 31, 159-165, 1995).

Patent applications WO 96/12963, WO 96/13484, WO96/19451, WO 97/02242,

15 WO97/217675, WO97/217676, WO 96/41098, and WO97/41099 (SmithKline Beecham plc) disclose *inter alia* various series of 4-thionyl/sulfinyl/sulfonyl azetidinone compounds which are inhibitors of the enzyme Lp-PLA₂. These are irreversible, acylating inhibitors (Tew *et al*, Biochemistry, **37**, 10087, 1998).

20 WO 99/24420 (SmithKline Beecham) describes a new class of compounds which are inhibitors of Lp-PLA₂, namely a group of pyrimidone compounds. We have now identified a particular subset of pyrimidone compounds which have a 5-(2-oxopyrimid-5-ylmethyl) substituent and which are potent inhibitors of Lp-PLA₂

25 Accordingly, the present invention provides a compound of the formula (I):



(I)

in which:

- 30 R¹ is COOH or a salt thereof, COOR¹⁰, CONR¹¹R¹², CN or CH₂OH;
 R² is a mono- or bicyclic aromatic ring system containing up to 10 carbon atoms in the ring system, or a mono- or bicyclic heteroaromatic ring system including up to 4 heteroatoms selected from N, O and S; optionally substituted by 1, 2, 3 or 4 substituents

selected from C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkylthio, aryl, aralkyl, hydroxy, oxo, halogen, CN, COOH or a salt thereof, COO-C₁₋₆alkyl, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, SO₂NR¹⁵R¹⁶, NR¹⁵SO₂R¹⁶, NR¹⁵R¹⁶, mono to perfluoro C₁₋₄alkyl and mono to perfluoro C₁₋₄alkoxy;

R³ is C₁₋₂₀ alkyl, C₃₋₆ cycloalkyl, C₃₋₆cycloalkylC₁₋₅alkyl, or C₁₋₁₀

5 alkoxyC₁₋₁₀ alkyl, each optionally substituted by 1 or 2 substituents selected from hydroxy, C₁₋₁₀ alkoxy, COOH or a salt thereof, COOC₁₋₁₅ alkyl, CONR¹⁷R¹⁸, NR¹⁷R¹⁸, NR¹⁷COR¹⁸, NR¹⁹ or an aromatic or heteroaromatic ring system as defined for R², or R³ is an aromatic or heteroaromatic ring system as hereinbefore defined for R²;

10 R¹⁰ is C₁₋₄alkyl or a pharmaceutically acceptable *in vivo* hydrolysable ester group;

R¹¹ and R¹² which may be the same or different is each selected from hydrogen, C₁₋₁₂alkyl, CH₂R¹³, CHR¹⁴CO₂H or a salt thereof, or R¹¹ and R¹² together with the nitrogen to which they are attached form a 5- to 7 membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and
15 optionally substituted by one or two substituents selected from hydroxy, oxo, C₁₋₄alkyl, C₁₋₄alkylCO, aryl, e.g. phenyl, or aralkyl, e.g. benzyl, for instance morpholine or piperazine;

R¹³ is COOH or a salt thereof, COOR¹⁰, CONR¹¹R¹², CN or CH₂OH;

R¹⁴ is an amino acid side chain such as CH₂OH from serine;

20 R¹⁵ and R¹⁶ are independently hydrogen or C₁₋₄ alkyl e.g. methyl or ethyl;

R¹⁷ and R¹⁸ are independently hydrogen, C₁₋₁₅ alkyl, eg methyl or ethyl, C₁₋₁₀ alkoxyC₁₋₁₀ alkyl or arylC₁₋₁₀ alkyl, e.g. benzyl;

R¹⁹ together with the nitrogen atom to which it is attached forms a 5- to 7 membered ring optionally containing one or more further heteroatoms selected from
25 oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C₁₋₄ alkyl, aryl, e.g. phenyl, or aralkyl, e.g. benzyl;

W is SO₂ or a bond;

X is O or S; and

30 Y is a group of the formula -A¹-A²-A³- in which A¹ and A³ each represent a bond or a straight chain or branched alkylene group, said alkylene group(s) containing a total of 1 to 10 carbon atoms and A² represents a bond or O, S, SO, SO₂, CO, C=CH₂, CONH, NHCO, CR¹⁵R¹⁶, CH=CH or C≡C, providing that when A² is O, S, SO, SO₂ or CONH, A³ contains at least two carbon atoms linking the A² group and the CH₂ group in formula (I).

35

Representative examples of R¹ include carboxy (COOH) and corresponding salts, esters (COOR¹⁰) and amides (CONR¹¹R¹²) thereof, for instance a sodium salt, an ethyl ester or an amide comprising an N-alkyl substituent, for instance, methyl, 2-methoxyethyl,

octyl, dodecyl, N-benzyl, N-naphthylmethyl or a disubstituted amide comprising a combination thereof, or an amide in which the N forms part of a heterocyclic ring, for instance a piperidine ring.

- 5 Representative examples of the aromatic ring system represented by R^2 include phenyl and naphthyl. Representative examples of the heteroaromatic ring system which may be represented by R^2 include pyridyl, pyrimidinyl, pyrazolyl, furanyl, thienyl, thiazolyl, quinolyl, benzothiazolyl, pyridazolyl and pyrazinyl. Representative examples of R^2 include the phenyl group optionally substituted by 1, 2 or 3 substituents selected from
 10 halogen (e.g. chlorine or fluorine), C_{1-4} alkyl (e.g. methyl or ethyl) or C_{1-4} alkoxy (e.g. methoxy), for instance 4-fluorophenyl. Examples of the aryl and aralkyl substituents in the R^2 group include respectively phenyl and benzyl.

- Representative examples of R^3 include C_{1-20} alkyl, for instance methyl and undecyl, and
 15 $R^{17}R^{18}NHCOCH_2$ in which R^{17} and R^{18} is each independently C_{1-15} alkyl, for instance R^{17} is methyl and R^{18} is methyl, octyl, or dodecyl.

Preferably, W is a bond.

- 20 Preferably, R^3W is N-(1-Dodecyl)-N-methylaminocarbonylmethyl.

The group X is preferably S.


- Preferred compounds of formula (I) include those in which Y is a bond, i.e. A^1 , A^2 and
 25 A^3 each representing a bond. Other preferred examples of the groups A^1 and A^3 are straight chain alkylene groups. When A^2 is other than a bond, A^1 is preferably a bond. Preferred examples of A^2 above include CO, $C=CH_2$ and O, the CO group being especially preferred. Other preferred examples of Y are $(CH_2)_7$ or $CO(CH_2)_6$.

- 30 Pharmaceutically acceptable *in vivo* hydrolysable ester groups for R^{10} include those which break down readily in the human body to leave the parent acid or its salt.


Representative examples of values of pharmaceutically acceptable *in vivo* hydrolysable ester groups for R^{10} include:

- 35 $-CH(R^a)O.CO.R^b$;
 $-CH(R^a)O.CO.OR^c$;
 $-CH(R^a)CO.NR^eR^f$
 $-R^dNR^eR^f$;

-CH₂OR^g;



CH(R^a)O.CO.C₆H₄Y¹COCH(Rⁱ)NH₂; and



5 in which:

R^a is hydrogen, (C₁-6)alkyl, in particular methyl, (C₃-7)cycloalkyl, or phenyl, each of which may be optionally substituted;

R^b is (C₁-6)alkyl, (C₁-6)alkoxy(C₁-6)alkyl, phenyl, benzyl, (C₃-7)cycloalkyl, (C₁-6)alkyl(C₃-7)cycloalkyl, 1-amino(C₁-6)alkyl, or 1-(C₁-6alkyl)amino(C₁-6)alkyl,

10 each of which may be optionally substituted; or

R^a and R^b together form a 1,2-phenylene group optionally substituted by one or two methoxy groups;

R^c is (C₁-6)alkyl, (C₃-7)cycloalkyl, (C₁-6)alkyl(C₃-7)cycloalkyl;

R^d is (C₁-6)alkylene optionally substituted with a methyl or ethyl group;

15 R^e and R^f which may be the same or different is each (C₁-6)alkyl; or aryl(C₁-4) alkyl, optionally substituted with e.g. hydroxy;

R^g is (C₁-6)alkyl;

R^h is hydrogen, (C₁-6)alkyl or phenyl;

Rⁱ is hydrogen or phenyl optionally substituted by up to three groups selected from

20 halogen, (C₁-6)-alkyl, or (C₁-6)alkoxy;

and

Y¹ is oxygen or NH;

for instance:

(a) acyloxyalkyl groups such as acetoxymethyl, isobutyryloxymethyl,

25 pivaloyloxymethyl, benzoyloxymethyl, α-acetoxyethyl, α-pivaloyloxyethyl, 1-(cyclohexylcarbonyloxy)ethyl, (1-aminoethyl)carbonyloxymethyl, 2-methoxyprop-2-ylcarbonyloxymethyl, phenylcarbonyloxymethyl and 4-methoxyphenyl-carbonyloxymethyl;

(b) alkoxy/cycloalkoxycarbonyloxyalkyl groups, such as ethoxycarbonyloxymethyl, t-butylloxycarbonyloxymethyl, cyclohexyloxycarbonyloxymethyl, 1-methylcyclohexyloxycarbonyloxymethyl and α-ethoxycarbonyloxyethyl;

30

- (c) dialkylaminoalkyl, especially di-loweralkylamino alkyl groups such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl;
- (d) acetamido groups such as N,N-dimethylaminocarbonylmethyl, N,N-(2-hydroxyethyl)aminocarbonylmethyl;
- 5 (e) lactone groups such as phthalidyl and dimethoxyphthalidyl;
- (f) (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl; and
- (g) (2-methoxycarbonyl-*E*-but-2-en-yl)methyl.

Representative examples of pharmaceutically acceptable *in vivo* hydrolysable ester groups
 10 for R¹⁰ include:

- (2-methoxycarbonyl-*E*-but-2-en-yl)methyl, isobutyryloxymethyl, 2-methoxyprop-2-ylcarbonyloxymethyl, phenylcarbonyloxymethyl, 4-methoxyphenyl-carbonyloxymethyl, t-butyloxycarbonyloxymethyl, cyclohexyloxy-carbonyloxymethyl, 1-methylcyclohexyloxycarbonyloxymethyl, N,N-dimethylaminocarbonylmethyl, and (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl.
- 15

When used herein, the term "alkyl" and similar terms such as "alkoxy" include all straight chain and branched isomers.

- 20 It will be appreciated that in some instances, compounds of the present invention may include a carboxy group as a substituent. Such carboxy groups may be used to form salts, in particular pharmaceutically acceptable salts. Pharmaceutically acceptable salts include those described by Berge, Bighley, and Monkhouse, *J. Pharm. Sci.*, 1977, **66**, 1-19. Preferred salts include alkali metal salts such as the sodium and potassium salts.

25

Compounds of formula (I) are inhibitors of Lp-PLA₂ and as such are expected to be of use in treating atherosclerosis and the other disease conditions noted elsewhere. Such compounds are found to act as inhibitors of Lp-PLA₂ in *in vitro* assays .

- 30 Particularly preferred compounds of formula (I) include:
- 1-(N-(1-Octyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-carboxymethyl-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one;
- 1-(N-(1-Octyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-(methylaminocarbonylmethyl)-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one;
- 35 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-(methylaminocarbonylmethyl)-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one;

1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-(1-morpholinocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one; and
1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-carboxymethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one and the sodium salt thereof.

5

Since the compounds of the present invention, in particular compounds of formula (I), are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations
10 of the compounds of formula (I) may be used for preparing the more pure forms used in the pharmaceutical compositions. Although the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of formula (I). Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form.

15

When some of the compounds of this invention are allowed to crystallise or are recrystallised from organic solvents, solvent of crystallisation may be present in the crystalline product. This invention includes within its scope such solvates. Similarly, some of the compounds of this invention may be crystallised or recrystallised from
20 solvents containing water. In such cases water of hydration may be formed. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. In addition, different crystallisation conditions may lead to the formation of different polymorphic forms of crystalline products. This invention includes within its
25 scope all polymorphic forms of the compounds of formula (I).

Compounds of the present invention are inhibitors of the enzyme lipoprotein associated phospholipase A₂ (Lp-PLA₂) and as such are expected to be of use in therapy, in particular in the treatment of atherosclerosis. In a further aspect therefore the present
30 invention provides a compound of formula (I) for use in therapy.

The compounds of formula (I) are inhibitors of lysophosphatidylcholine production by Lp-PLA₂ and may therefore also have a general application in any disorder that involves endothelial dysfunction, for example atherosclerosis, diabetes, hypertension, angina
35 pectoris and after ischaemia and reperfusion. In addition, compounds of formula (I) may have a general application in any disorder that involves lipid peroxidation in conjunction with enzyme activity, for example in addition to conditions such as atherosclerosis and diabetes, other conditions such as rheumatoid arthritis, stroke, inflammatory conditions of

the brain such as Alzheimer's Disease, myocardial infarction, reperfusion injury, sepsis, and acute and chronic inflammation. Further such conditions include various neuropsychiatric disorders such as schizophrenia (see Psychopharmacology Bulletin, 31, 159-165, 1995).

5

Further applications include any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA₂. Examples of such disorders include psoriasis.

- 10 Accordingly, in a further aspect, the present invention provides for a method of treating a disease state associated with activity of the enzyme Lp-PLA₂ which method involves treating a patient in need thereof with a therapeutically effective amount of an inhibitor of the enzyme. The disease state may be associated with the increased involvement of monocytes, macrophages or lymphocytes; with the formation of lysophosphatidylcholine
15 and oxidised free fatty acids; with lipid peroxidation in conjunction with Lp PLA₂ activity; or with endothelial dysfunction.

- Compounds of the present invention may also be of use in treating the above mentioned disease states in combination with anti-hyperlipidaemic or anti-atherosclerotic or anti-
20 diabetic or anti-anginal or anti-inflammatory or anti-hypertension agents. Examples of the above include cholesterol synthesis inhibitors such as statins, anti-oxidants such as probucol, insulin sensitisers, calcium channel antagonists, and anti-inflammatory drugs such as NSAIDs.


- 25 In therapeutic use, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides, in a further aspect, a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.

- 30 Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository. Compounds of formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges. A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable
35 liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent. A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of

such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule. Typical parenteral compositions consist of a solution or suspension of the compound of formula (I) in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration. A typical suppository formulation comprises a compound of formula (I) which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.

Preferably the composition is in unit dose form such as a tablet or capsule. Each dosage unit for oral administration contains preferably from 1 to 500 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I). The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 1000 mg, preferably between 1 mg and 500 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the formula (I), the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.

Compounds of formula (I) may be conveniently prepared by a process which comprises reacting a compound of formula (II):




(II)

in which R^2 , R^3 , W, X and Y are as hereinbefore defined;

with an alkylating agent of formula $R^1-CH_2-L^1$ in which R^1 is as hereinbefore defined and L^1 is a leaving group such as chloride, bromide, iodide or mesylate, in the presence of a base such as potassium carbonate; and thereafter, and if necessary, interconverting groups in R^1 , for example $COOR^{10}$ to $COOH$ by standard conditions (alkaline hydrolysis, hydrogenation of benzyl ester, etc), or $COOH$ to $CONR^{11}R^{12}$ by amide coupling.


A compound of formula (II) can conveniently be prepared by O-dealkylation of the corresponding compound of formula (III):



(III)

in which R^{20} is C_{1-4} alkyl, arylmethyl or diarylmethyl and R^2 , R^3 , W , X and Y are as hereinbefore defined. Typical conditions include treatment with boron tribromide or B-bromocatecholborane in dichloromethane at temperatures between -20° and ambient; hydrogenolysis of benzyloxy groups; acid cleavage of O-tBu.

A compound of formula (III) may be readily prepared in a series of steps from a compound of formula (IV):




(IV)

in which R^{21} is hydrogen or C_{1-4} alkyl, for instance methyl or ethyl, R^{22} is hydrogen or methyl and R^{20} is as hereinbefore defined; using procedures well known in the art for thiouracil formation, N-alkylation and thioetherification.

Thus, for instance, for a compound of formula (III) in which W is a bond, a compound of formula (IV) in which R²¹ is hydrogen and R²² is methyl may be treated with oxalyl chloride in a dry solvent such as dichloroethane, to form an intermediate acyl chloride, followed by treatment with potassium thiocyanate in the presence of a solvent such as acetonitrile, and then treatment with a compound of the formula (V):



in which W is a bond and R³ is as hereinbefore defined; followed by the addition of a base such as sodium ethoxide, to give a thiouracil compound of the formula (VI):




in which R³, R²⁰ and W are as hereinbefore defined. The compound of formula (VI) may then be treated with a compound of the formula (VII):




in which L¹ and R² are as hereinbefore defined; to give a compound of formula (III) in which X is S.

In an alternative approach, a compound of formula (IV) in which R²¹ is C₁₋₄alkyl, for instance methyl, and R²² is methyl, may be treated with thiourea, to form a thiouracil of the formula (VIII):



(VIII)

in which R^{20} is a hereinbefore defined. This thiouracil may then be treated with a compound of the formula (VII) as hereinbefore described, to give a compound of formula (IX):



(IX)

in which R^2 , R^{20} and Y are as hereinbefore defined and X is S . Subsequent reaction of a compound of formula (IX) with a compound of the formula (X):



(X)

in which L^1 , R^3 and W are as hereinbefore defined; leads to a compound of formula (III) in which X is S .

- Compounds of formula (IV) may be readily obtained from a convenient, readily available pyrimidine starting material such as a 2-alkoxy 5-bromopyrimidine, using processes well known in the art. This pyrimidine may be coupled with an acrylate ester such as ethyl or methyl acrylate, using a Heck reaction, and the intermediate then subjected to catalytic hydrogenation to give a propionic acid ester derivative. This in turn may be treated with methyl formate in the presence of a strong base such as potassium t-butoxide or sodium hydride, to give a compound of formula (IV) in which R^{22} is hydrogen. Alkylation, for instance methylation, using dimethyl sulphate, then gives a compound of formula (IV) in which R^{22} is alkyl. A compound of formula (IV) in which R^{21} is hydrogen (ie the carboxylic acid) may be obtained from the corresponding ester by hydrolysis under basic conditions, for instance aqueous sodium hydroxide.


Compounds of formula (I) in which X is O may be conveniently be prepared from corresponding compounds of formula (I) in which X is S by treatment thereof with a compound of the formula (XI):



(XI)


in which R^2 is as hereinbefore defined.

The present invention will now be illustrated by the following examples:

Intermediate 1 - N-(1-Dodecyl)-N-methylbromoacetamide


To a solution of N-methyl-N-dodecylamine (2.5 ml) and triethylamine (1.4 ml) in dichloromethane (10 ml) was added with stirring and ice cooling a solution of
 5 bromoacetyl bromide (0.87 ml) in dichloromethane (10 ml). The cooling bath was removed after 30 min and the reaction stood for 16 h at ambient temperature. The mixture was washed with water and saturated sodium hydrogen carbonate, dried (K_2CO_3) and the solution purified by flash chromatography (silica, methanol-dichloromethane). Appropriate fractions were combined and evaporated to a pale yellow oil, yield 1.53 g

10 (48%).
 1H -NMR ($CDCl_3$) δ 0.8 (3H,t), 1.2 (18H,m), 1.5 (2H,m), 2.88 and 2.99 (3H,2xs), 3.27 (2H,m), 3.77 and 3.79 (2H,s); MS (APCI+) found ($M+1$) = 320, 322, $C_{15}H_{30}BrNO$ requires 319,321.

Intermediate 2 - N-(1-Octyl)-N-methylbromoacetamide


Prepared analogously to intermediate 1, from N-methyl-N-octylamine.

15 1H -NMR ($CDCl_3$) δ 0.85-1.0 (3H,m), 1.1-1.4 (10H,m), 1.4-1.75 (2H,m), 2.95 and 3.07 (3H, 2xs), 3.25-3.45 (2H,m), 3.85 and 3.86 (2H,s); MS (APCI+) found ($M+1$) = 264, 266, $C_{15}H_{30}BrNO$ requires 319,321.

Intermediate 3 - Ethyl 3-(2-methoxypyrimidin-5-yl)acrylate

A mixture of 2-methoxy-5-bromopyrimidine (75.43 g, 0.399 mol), ethyl acrylate (47.5
 25 ml, 0.439 mol), palladium (II) acetate (1.07 g, 0.0048 mol), tri-*o*-tolylphosphine (2.92 g, 0.0096 mol) and triethylamine (84 ml) were heated at 135°C with stirring under argon for 12 h. After allowing to cool the solid mass was dissolved in water and ethyl acetate, filtered, and the aqueous phase separated and further extracted with ethyl acetate. The combined extracts were washed with saturated aqueous ammonium chloride, dried
 30 ($MgSO_4$) and evaporated. The solid thus obtained was triturated with ether/light petrol (1:3, 350 ml), filtered, washed and dried, yield 52.41 g (63%).

1H -NMR ($CDCl_3$) δ 1.33 (3H, t), 4.06 (3H, s), 4.28 (2H, q), 6.45 (1H, d), 7.58 (1H, d), 8.67 (2H, s); MS (APCI+) found ($M+H$) = 209; $C_{10}H_{12}N_2O_3$ requires 208.


Intermediate 4 - Ethyl 3-(2-methoxypyrimidin-5-yl)propionate

A suspension of ethyl 3-(2-methoxypyrimidin-5-yl)acrylate (52.4 g, 0.252 mol) in ethanol (400 ml) and triethylamine (50 ml) was treated with 10% palladium on carbon (3 g) and hydrogenated at 50 psi for 1.75 h. The catalyst was filtered off through hyflo and the

filtrate evaporated. The residue was dissolved in dichloromethane, washed twice with saturated aqueous ammonium chloride, dried (MgSO_4) and evaporated to an oil, yield 41.2 g (78%).

$^1\text{H-NMR}$ (CDCl_3) δ 1.23 (3H, t), 2.61 (2H, t), 2.87 (2H, t), 3.99 (3H, s), 4.13 (2H, q), 8.39 (2H, s); MS (APCI+) found ($\text{M}+\text{H}$) = 211; $\text{C}_{10}\text{H}_{14}\text{N}_2\text{O}_3$ requires 210.


Intermediate 5 - 2-(Methoxymethylene)-3-(2-methoxypyrimidin-5-yl)propionic acid, mixed methyl/ethyl esters



To a stirring suspension of sodium hydride (0.83 g of a 60% dispersion in oil) in anhydrous 1, 2-dimethoxyethane (6 ml) was added dropwise a solution of methyl formate (1.54 ml) and ethyl 3-(2-methoxypyrimidin-5-yl)propionate (3.5 g) in anhydrous 1,2-dimethoxyethane (6 ml) at such a rate as to maintain the reaction temperature at 25-30°C. After 1 h, ether was added and the precipitated oil allowed to settle. The solution was decanted off and replaced with fresh ether, and the oil slowly solidified. The solid 2-(hydroxymethylene) derivative was filtered, washed and dried, yield 3.8 g. A 1.33 g portion was suspended in dimethyl formamide (10 ml) together with anhydrous potassium carbonate (1.15 g), and a solution of dimethyl sulphate (0.48 ml) in dimethylformamide (10 ml) was added dropwise with stirring over 30 min. After 16 h the solvent was evaporated and the residue treated with water and extracted with ethyl acetate. The extracts were washed with water, dried (MgSO_4) and evaporated to give the product as an oil, yield 0.91 g.

$^1\text{H-NMR}$ (CDCl_3) δ 1.23 (3H, t), 3.46 (2H, s), 3.69 (3H, s, methyl ester), 3.88 (3H, s), 3.97 (3H, s), 4.16 (2H, q), 7.39 (1H, s), 8.40 (2H, s). 3:2 ratio of methyl:ethyl esters. MS (APCI+) found ($\text{M}+1$) = 253, 239 (ethyl and methyl esters); $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_4$ requires 252, $\text{C}_{11}\text{H}_{14}\text{N}_2\text{O}_4$ requires 238.


Intermediate 6 - 2-(Methoxymethylene)-3-(2-methoxypyrimidin-5-yl)propionic acid



A suspension of the mixed esters of intermediate 5 (0.9 g) in 2M aqueous sodium hydroxide (3.6 ml) was stirred at ambient temperature for 16 h to give a clear solution. This was diluted with water, extracted with dichloromethane and evaporated to about half volume, then acidified to pH 3-4 (2M hydrochloric acid) when the product crystallised out. The white solid was filtered, washed with ice-cold water and dried, yield 0.46 g.

$^1\text{H-NMR}$ (CDCl_3) δ 3.43 (2H, s), 3.91 (3H, s), 3.99 (3H, s), 7.49 (1H, s), 8.42 (2H, s); MS (APCI+) found ($\text{M}+1$) = 225, $\text{C}_{10}\text{H}_{12}\text{N}_2\text{O}_4$ requires 224.

Intermediate 7 - 5-(2-Methoxypyrimidin-5-ylmethyl)-2-thiouracil




To an ice cooled solution of potassium t-butoxide (7.83 g, 0.07 mol) in anhydrous THF (60 ml) was added dropwise with stirring under argon over 1 hour to a solution of ethyl 3-(2-methoxypyrimidin-5-yl) propionate (5.87 g, 0.028 mol) and methyl formate (3.6 ml, 0.059 mol) in anhydrous ether (70 ml). After stirring for 16 h, the solvents were

5 evaporated, thiourea (4.25 g, 0.056 mol) and propan-2-ol (80 ml) added and the mixture refluxed for 5 h. The solvent was evaporated and the residue dissolved in water, extracted twice with ether and acidified to pH 4.5 with acetic acid. The solid which precipitated was filtered, washed well with water and dried, yield 5.57 g (80%).

¹H-NMR (d₆-DMSO) δ 3.47 (2H, s), 3.85 (3H, s), 7.43 (1H, s), 8.48 (2H, s), 12.25 (1H, br s), 12.46 (1H, br s); MS (APCI+) found (M+H) = 251; C₁₀H₁₀N₄O₂S requires 250.

10

Intermediate 8 - 1-(1-Undecyl)-5-(2-ethoxypyrimidin-5-ylmethyl)-2-thiouracil



To a slurry of 2-(methoxymethylene)-3-(2-methoxypyrimidin-5-yl)propionic acid (3.1 g) in dry dichloroethane (50ml) was added oxalyl chloride (2.5ml). The mixture was stirred at room temperature for 4h and the solvent was removed *in vacuo*. Further dichloroethane (50ml) was added and removed *in vacuo*. The residue was mixed with acetonitrile (50ml) and dry potassium thiocyanate (2.0g) added. The mixture was stirred under argon for 21h and the solvent removed *in vacuo*. The residue was mixed with


20 dimethylformamide and 1-undecylamine (3.0ml) added with stirring, followed by triethylamine (5ml). The mixture was stirred at room temperature under argon for 20h and a solution of sodium ethoxide in ethanol (3M, 19ml) was added. The reaction was heated at 90°C for 2h, cooled and the solvent was removed *in vacuo*. The residue was dissolved in water and glacial acetic acid was added to pH4.5. The solid so formed was

25 filtered, evaporated with ethanol (100ml) *in vacuo* and dried *in vacuo* to give the desired product (5g).

¹H-NMR (d₆ DMSO) δ 0.75-0.95 (3H,m), 1.1-1.8 (21H,m), 3.49 (2H,s), 4.11 (2H,t), 4.31 (2H,q), 7.87 (1H,s) 8.47 (2H,s); MS (APCI+) found (M+1) = 419; C₂₂H₃₄N₄O₂S requires 418.

30


Intermediate 9 - 1-(1-Undecyl)- 5-(2-methoxypyrimid-5-ylmethyl)-2-thiouracil



Prepared analogously to intermediate 8, except using sodium methoxide in place of ethoxide.


¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,t), 1.1-1.85 (18H,m), 3.59 (2H, s), 4.01 (3H,s), 4.11 (2H,t), 7.04 (1H,s), 8.43 (2H, s); MS (APCI+) found (M+1) = 405; C₂₁H₃₂N₄O₂S requires 404.

35

Intermediate 10 - 1-(1-Undecyl)-2-(4-fluorobenzylthio)-5-(2-ethoxypyrimidin-5-ylmethyl)pyrimidin-4-one


To a mixture of 1-undecyl-5-(2-ethoxypyrimidin-5-ylmethyl)-2-thiouracil (5.0g) and diisopropylethylamine (2.1ml) in dry methylene chloride (200ml) was added 4-fluorobenzyl bromide (1.5ml) and the mixture stirred under argon at room temperature for 20h. The solution was washed with 5% aqueous sodium bicarbonate and the organic layer was added directly to a silica gel column (200g). Elution with ethyl acetate to 5% methanol in ethyl acetate gave the desired product (2.7g).

¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,m), 1.15-1.4 (16H,m), 1.43 (3H,t), 1.55-1.8 (2H,m), 3.68 (2H,s), 3.71 (2H,t), 4.41 (2H,q), 4.47 (2H,s), 6.86 (1H,s), 6.9-7.1 (2H,m), 7.3-7.45 (2H,m), 8.45 (2H,d); MS (APCI+) found (M+1) = 527; C₂₉H₃₉FN₄O₂S requires 526.

Intermediate 11 - 2-(4-Fluorobenzylthio)-5-(2-methoxypyrimidin-5-ylmethyl)pyrimidin-4-one

Prepared analogously to intermediate 10, from 5-(2-methoxypyrimidin-5-ylmethyl)-2-thiouracil.


¹H-NMR (d₆ DMSO) δ 3.55 (2H,s), 3.85 (3H,s), 4.36 (2H,s), 7.0-7.2 (2H,m), 7.35-7.5 (2H,m), 7.86 (1H,bs), 8.48 (2H,s) 12.81 (1H,b); MS (APCI+) found (M+1) = 359; C₁₇H₁₅FN₄O₂S requires 358.

Intermediate 12 - 1-Methyl-2-(4-fluorobenzylthio)-5-(2-methoxypyrimidin-5-ylmethyl)pyrimidin-4-one

To a solution of intermediate 11 (10.2g) and diisopropylethylamine (6.0ml) in dry methylene chloride (120ml) was added iodomethane (1.7ml) under argon with stirring. The mixture was left at room temperature for 48h, washed with saturated ammonium chloride and saturated sodium bicarbonate and added directly to a silica (200g) column.

Elution with 2% to 10% methanol in ethyl acetate gave the desired product (2.5g). ¹H-NMR (CDCl₃) δ 3.47 (3H,s), 3.64 (2H,t), 3.99 (3H,s), 4.47 (2H,s), 6.88 (1H,s), 6.9-7.1 (2H,m), 7.3-7.5 (2H,m), 8.44 (2H,s); MS (APCI+) found (M+1) = 373; C₁₈H₁₇FN₄O₂S requires 372.


Intermediate 13 - 1-(N-Methyl-N-(1-octyl)aminocarbonylmethyl)-2-(4-fluorobenzylthio)-5-(2-methoxypyrimidin-5-ylmethyl)pyrimidin-4-one



Prepared analogously to intermediate 12, using N-(1-octyl)-N-methylbromoacetamide in place of iodomethane.

¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,m), 1.1-1.7 (12H,m), 2.95 and 2.99 (3H,2xs), 3.21 and 3.36 (2H, 2xt), 3.66 (2H,s), 3.99 (3H,s), 4.48 (2H,s), 4.51 and 4.55 (2H,d), 6.80 (1H,s), 6.9-7.1 (2H,m), 7.3-7.45 (2H,m), 8.45 (2H,s); MS (APCI+) found (M+1) = 542; C₂₈H₃₆FN₅O₃S requires 541.


Intermediate 14 - 1-(N-Methyl-N-(1-dodecyl)aminocarbonylmethyl)-2-(4-fluorobenzylthio)-5-(2-methoxypyrimidin-5-ylmethyl)pyrimidin-4-one



A mixture of N-dodecyl-N-methylbromoacetamide (1.53g), 2-(4-fluorobenzylthio)-5-(2-methoxypyrimidin-5-ylmethyl)pyrimidin-4-one (1.71g) and N,N-diisopropylethylamine (0.92ml) in dichloromethane (7ml) was stirred at ambient temperature for 16h. The solution was washed with saturated ammonium chloride then purified by flash chromatography (fine silica, methanol-ethyl acetate) to give the product as a solid, yield 0.82g (29%).

¹H-NMR (CDCl₃) δ 0.85 (3H,t), 1.2 (18H,m), 1.5 (2H,m), 2.92 and 2.95 (3H,2xs), 3.17 and 3.33 (2H,2xm), 3.63 (2H,s), 3.96 (3H,s), 4.45 (2H,s), 4.49 and 4.52 (2H,2xs), 6.79 (1H,s), 6.95 (2H,m), 7.30 (2H,m), 8.42 (2H,s); MS (APCI+) found (M+1) = 598, C₃₂H₄₄FN₅O₃S requires 597.


Intermediate 15 - 1-(1-Undecyl)-2-(4-fluorobenzylthio)-5-(2-methoxypyrimidin-5-ylmethyl)pyrimidin-4-one



Prepared analogously to intermediate 10, from 1-undecyl-5-(2-methoxypyrimidin-5-ylmethyl)-2-thiouracil

¹H-NMR (CDCl₃) δ 0.88 (3H, t), 1.25 (16H, m), 1.68 (2H, m), 3.64 (2H, s), 3.71 (2H, t), 4.00 (3H, s), 4.47 (2H, s), 6.87 (1H, s), 7.00 (2H, m), 7.36(2H, m), 8.46(2H, s); MS (APCI+) found (M+H) = 513; C₂₈H₃₇N₄O₂S requires 512.


Intermediate 16 - 1-(1-Undecyl)-2-(4-fluorobenzylthio)-5-(2-oxypyrimidin-5-ylmethyl)pyrimidin-4-one



To a solution of intermediate 15 (0.2g) in dry methylene chloride (4ml) at 4°C was added boron tribromide (1M in methylene chloride, 2ml). The mixture was stirred under argon for 24h and poured into a mixture of ice (50ml) and 0.880 ammonia (15ml) with stirring. Extraction with 5% methanol in methylene chloride was followed by filtration through kieselguhr and drying the organic layer over sodium sulphate. Removal of the solvent *in vacuo* gave the desired material as a grey solid (0.15g). The same material could be prepared from intermediate 10 by an identical method.


¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,m), 1.1-1.4 (16H,m), 1.6-1.85 (2H,m), 3.49 (2H,s), 3.79 (2H,t), 4.45 (2H,s), 6.9-7.1 (2H,m), 7.2-7.45 (3H,m), 8.32 (2H,s); MS (APCI+) found (M+1) = 499; C₂₇H₃₅FN₄O₂S requires 498.

Intermediate 17 - 1-(N-Methyl-N-(1-octyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



Prepared analogously to intermediate 16, from 1-(N-methyl-N-(1-octyl)aminocarbonylmethyl)-2-(4-fluorobenzylthio)-5-(2-methoxypyrimid-5-ylmethyl)pyrimidin-4-one, except that the reaction was performed at 5°C (ice-bath) for 4-6h. ¹H-NMR (d₆ DMSO) δ 0.8-0.95 (3H,m), 1.05-1.65 (12,m), 2.81 and 2.94 (3H,2xs), 3.15-3.4 (4H,m), 4.39 (2H,s), 4.83 and 4.85 (2H,2xd), 7.05-7.2 (2H,m), 7.35-7.55 (3H,m), 7.95-8.35 (2H,b); MS (APCI+) found (M+1) = 526; C₂₇H₃₅FN₄O₂S requires 525.


Intermediate 18 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



To a solution of intermediate 12 (5g) in dry methylene chloride was added a solution of boron tribromide 1M in dichloromethane (50ml) at 5°C under argon with stirring. After 0.5h, the mixture was allowed to warm to room temperature and was allowed to stir at room temperature for 72h. The mixture was decanted into a mixture of ice (50ml) and 0.880 ammonia (50ml). The solid remaining in the flask was treated with some of the aqueous mixture and 10% methanol in methylene chloride. The entire mixture was filtered through kieselguhr and the organic layer was separated. The aqueous layer was reduced to one quarter volume *in vacuo* and the solid formed filtered off, washed with water and dried *in vacuo* to give the desired product (2.2g).

¹H-NMR (d₆ DMSO) δ 3.30 (2H,s), 3.47 (3H,s), 4.41 (2H,s), 7.05-7.25 (2H,m), 7.4-7.55 (2H,m), 7.65 (1H,s), 7.85-8.3 (2H,b); MS (APCI+) found (M+1) = 359; C₁₇H₁₅FN₄O₂S requires 358.


5 Example 1 - 1-(1-Undecyl)-2-(4-fluorobenzyl)thio-5-(1-(ethoxycarbonylmethyl)-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one



To a solution of intermediate 16 (0.64g) in dry dimethylformamide (15ml) was added ethyl bromoacetate (0.15ml) and potassium carbonate (0.38g). The mixture was heated at 70°C for 3h under argon with stirring. The dimethylformamide was removed *in vacuo* and the residue was partitioned between aqueous ammonium chloride (30ml) and methylene chloride. The aqueous layer was washed with further methylene chloride and the combined organic layers were added directly to a SepPak cartridge (SiO₂, 10g) and eluted with 0 - 15% methanol in ethyl acetate. This gave the desired product as a gum (0.63g).

¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,m), 1.15-1.4 (19H,m), 1.65-1.85 (2H,m), 3.47 (2H,s), 3.7 (2H,t), 4.25 (2H,q), 4.46 (2H,s), 4.61 (2H,s), 6.9-7.1 (2H,m), 7.12 (1H,s), 7.3-7.45 (2H,m), 7.87 (1H,bd), 8.5 (1H,bd); MS (APCI+) found (M+1) = 585; C₃₁H₄₁FN₄O₄S requires 584.

20 Example 2 - 1-(1-Undecyl)-2-(4-fluorobenzyl)thio-5-(1-(carboxymethyl)-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one




A solution of sodium hydroxide (0.023g) in water (1.25ml) was added to a solution of 1-undecyl-2-(4-fluorobenzyl)thio-5-(1-(carbethoxymethyl)-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one (0.33g) in dioxan (5ml) under argon. After 16h, the solvent was removed, almost to dryness, *in vacuo* and the residue dissolved in water (30ml).

Acidification to pH 1 with 2M hydrochloric acid gave a solid that was filtered, washed with water and dried *in vacuo* to give the desired product (0.14g) as a white solid.

¹H-NMR (d₆ DMSO) δ 0.8-0.95 (3H,m), 1.1-1.4 (16H,m), 1.55-1.8 (2H,m), 3.38 (2H,s), 3.81 (2H,t), 4.42 (2H,s), 4.62 (2H,s), 7.05-7.2 (2H,m), 7.4-7.55 (2H,m), 7.80 (1H,s), 8.22 (1H,bd), 8.65 (1H,bd).


35 Example 3 - 1-(1-Undecyl)-2-(4-fluorobenzyl)thio-5-(1-(dimethylaminocarbonylmethyl)-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one



A mixture of 1-undecyl-2-(4-fluorobenzyl)thio-5-(1-(carboxymethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one, dimethylamine hydrochloride (0.02g), diisopropylethylamine (0.045ml), hydroxybenzotriazole (0.005g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.045g) in dry methylene chloride were stirred together for 24h and diluted with 3% methanol in methylene chloride and 5% aqueous potassium carbonate. The organic layer was added directly to a SepPak cartridge (SiO₂, 10g) and eluted with 0 - 20% methanol in ethyl acetate to give the desired product (0.085g).

¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,m), 1.15-1.4 (16H,m), 1.6-1.85 (2H,m), 2.98 (3H,s), 3.13 (3H,s), 3.49 (2H,s), 3.77 (2H,t), 4.46 (2H,s), 4.74 (2H,s), 6.9-7.1 (2H,m), 7.14 (1H,s), 7.3-7.45 (2H,m), 7.78 (1H,bd), 8.49 (1H,bd); MS (APCI+) found (M+1) = 584; C₃₁H₄₂FN₅O₃S requires 583.


Example 4 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(ethoxycarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



Prepared analogously to example 1.

¹H-NMR (CDCl₃) δ 1.30 (3H,t), 3.48 (2H,s), 3.54 (3H,s), 4.22 (2H,q), 4.45 (2H,s), 4.61 (2H,s), 6.9-7.1 (2H,m), 7.3-7.5 (3H,m), 7.91 (1H,d), 8.6 (1H,d); MS (APCI+) found (M+1) = 445; C₂₁H₂₁FN₄O₄S requires 444.


Example 5 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(carboxymethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



Prepared analogously to example 2.

¹H-NMR (d₆ DMSO) δ 3.34 (2H,s), 3.48 (3H,t), 4.42 (2H,s), 4.55 (2H,s), 7.05-7.2 (2H,m), 7.4-7.6 (2H,m), 7.70 (1H,s), 8.01 (1H,bd), 8.58 (1H,bd).


Example 6 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(1-octylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



Prepared analogously to example 3.

¹H-NMR (d₆ DMSO) δ 0.8-0.95 (3H,t), 1.2-1.55 (12H, m), 3.05-3.2 (2H,m), 3.39 (2H,s), 3.52 (3H,s), 4.44 (2H,s), 4.47 (2H,s), 6.95-7.15 (2H,m), 7.4-7.55 (2H,m), 7.67 (1H,s), 7.95 (1H,d), 8.56 (1H,d); MS (APCI+) found (M+1) = 528; C₂₇H₃₄FN₅O₃S requires 527.


Example 7 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-benzyl-N-methylamino-carbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



Prepared analogously to example 3.

- 5 ¹H-NMR (CDCl₃) δ 3.00 and 3.04 (3H,2xs), 3.5 (3H,s + 2H,s), 4.47 (2H,s), 4.55-4.9 (2H,s), 6.9-7.1 (2H,m), 7.15-7.55 (8H,m), 7.75-7.9 (1H,m), 8.45-8.6 (1H,m).

Example 8 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-(1-dodecyl)-N-methylamino-carbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one




10

Prepared analogously to example 3.

¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,m), 1.1-1.75 (20H,m), 2.97 and 3.09 (3H,2xs), 3.35 (2H,t), 3.49 (2H,s), 3.52 (3H,s), 4.47 (2H,s), 4.72 (2H,s), 6.9-7.1 (2H,m), 7.23 (1H,s), 7.3-7.5 (2H,m), 7.77 (1H,bd), 8.48 (1H,bd); MS (APCI+) found (M+1) = 598;

- 15 C₃₂H₄₄FN₅O₃S requires 597.

Example 9 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-(2-methoxyethyl)-N-methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one




- 20 Prepared analogously to example 3.

¹H-NMR (CDCl₃) δ 2.98 and 3.17 (3H,2xs), 3.34 and 3.38 (3H,2xs), 3.4-3.7 (9H,s), 4.47 (2H,s), 4.75 and 4.81 (2H,2xs), 6.9-7.1 (2H,m), 7.18 and 7.20 (1H,2xs), 7.3-7.5 (2H,m), 7.7-7.85 (1H,m), 8.49 (1H,bd); MS (APCI+) found (M+23) = 510; C₂₃H₂₆FN₅O₄S requires 487.

25


Example 10 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-(naphth-1-ylmethyl)-N-methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



Prepared analogously to example 3.

¹H-NMR (CDCl₃) δ 2.99 and 3.12 (3H,2xs), 3.35-3.6 (5H,m), 4.46 and 4.47 (2H,2xs), 4.67 and 4.79 (2H,2xs), 5.07 and 5.17 (2H, 2xs), 6.9-7.1 (2H,m), 7.1-7.7 (7H,m), 7.7-8.05 (4H,m), 8.45-8.6 (1H,m); MS (APCI+) found (M+1) = 570; C₃₁H₂₈FN₅O₃S requires 569.


5 **Example 11 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(4-hydroxy-4-benzylpiperidin-1-yl)carbonylmethyl)-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one**



Prepared analogously to example 3.

10 ¹H-NMR (d₆ DMSO) δ 1.25-1.65 (4H,m), 2.71 (2H,s), 2.94, (1H,bt), 3.55-3.7 (1H,m), 3.95-4.1 (1H,m), 4.41 (3H,s), 4.65-4.85 (2H,m), 7.05-7.35 (7H,m), 7.4-7.6 (2H,m), 7.71 (1H,s), 7.87 (1H,d), 8.54 (1H,d); MS (APCI+) found (M+1) = 590; C₃₁H₃₂FN₅O₄S requires 589.


15 **Example 12 - 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-(1-octyl)-N-methylaminocarbonylmethyl)-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one**



Prepared analogously to example 3.

20 ¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,m), 1.10-1.65 (12H,m), 2.95 and 3.09 (3H,2xs), 3.35 (2H,t), 3.49 (2H,s), 3.52(3H,s), 4.47 (2H,s), 4.74 (2H,s), 6.9-7.1 (2H,m), 7.19 (1H,s), 7.3-7.5 (2H,m), 7.75 (1H,m), 8.48(1H,m); MS (APCI+) found (M+1) = 542; C₂₈H₃₆FN₅O₃S requires 541.


Example 13 - 1-(N-(1-Octyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-ethoxycarbonylmethyl-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one



25 Prepared analogously to example 1.

30 ¹H-NMR (CDCl₃) δ 0.8-1.0 (3H,m), 1.15-1.75 (15H,m), 2.94 and 3.00 (3H,2xs), 3.23 and 3.35 (2H,2xt), 3.47 (2H,s), 4.22 (2H,q), 4.46 (2H,s), 4.57 (2H,s), 4.73 and 4.75 (2H,2xs) 6.9-7.1 (2H,m), 7.35-7.45 (3H,m), 7.87 (1H,m), 8.44 (1H,m); MS (APCI+) found (M+1) = 614; C₃₁H₄₀FN₅O₅S requires 613.


Example 14 - 1-(N-(1-Octyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-carboxymethyl-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one



Prepared analogously to example 2 except that acidification was carried out with 10% aqueous NaHSO_4 to pH 3, and the crude product after filtration was recrystallised from acetonitrile.

- 5 $^1\text{H-NMR}$ (d_6 DMSO) δ 0.8-0.95 (3H,m), 1.1-1.65 (12H,m), 2.82 and 2.95 (3H,2xs), 4.40 (2H,s), 4.56 (2H,s), 4.84 and 4.85 (2H,2xs), 7.05-7.2 (2H,m), 7.35-7.50 (2H,m), 7.54 and 7.58 (1H,2xs), 8.04 (1H,d), 8.55 (1H,d); MS (APCI-) found (M-1) = 584; $\text{C}_{29}\text{H}_{36}\text{FN}_5\text{O}_5\text{S}$ requires 585.


10 **Example 15 - 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-ethoxycarbonylmethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one**



- 15 To a stirring solution of intermediate 14 (2.17 g) in dichloromethane (30 ml) was added dropwise with ice cooling a 1M solution of boron tribromide (21.8ml) such that the temperature remained between 5-10°C. After 4h the cooling bath was removed and stirring continued for 1.5h. The mixture was poured on to ice and 0.880 ammonia with stirring, diluted with more dichloromethane, shaken, and the phases allowed to separate slowly. The aqueous phase was further extracted with dichloromethane and the combined
- 20 extracts dried (MgSO_4) and evaporated. The crude material was purified by flash chromatography (fine silica, methanol-ethyl acetate) to give 0.9 g of material that was dissolved in dry dimethylformamide (15ml) and heated with ethyl bromoacetate (0.17ml) and anhydrous potassium carbonate (0.43g) (oil bath 70°C) with stirring for 2h. The solvent was evaporated and the residue treated with water and extracted with ethyl
- 25 acetate. The combined extracts were washed with water, dried (MgSO_4), evaporated and purified by flash chromatography (fine silica, methanol-ethyl acetate) to give the title compound as an oil, yield 0.52 g.

- 30 $^1\text{H-NMR}$ (CDCl_3) δ 0.88 (3H, t), 1.25 (21H, m), 1.45-1.75 (2H, m), 2.95, 3.00 (3H, 2xs), 3.20- 3.43 (2H, m), 3.48 (2H, s), 4.23 (2H, q), 4.47 (2H, s), 4.99 (2H, s), 4.66 (2H, m), 7.02 (2H, m), 7.15 and 7.18 (1H, 2xs), 7.37 (2H, m) 7.84 (1H, m), 8.47 (1H, m); MS (APCI+) found (M+1) = 670, $\text{C}_{35}\text{H}_{48}\text{FN}_5\text{O}_5\text{S}$ requires 669.


Example 16 - 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-carboxymethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



To a stirring solution of 1-(N-(1-dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-ethoxycarbonylmethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one in 1,4-dioxan (8 ml) was added 0.5M sodium hydroxide (1.56ml). After 1 h, water (3 ml) was added. After a further hour, the mixture was diluted with water, extracted with ethyl acetate and acidified to pH 3 with aq. sodium bisulphate. The solid which precipitated was filtered, washed with water and ether, heated briefly with acetone and filtered again to give the product as a white solid, yield 0.28 g.

¹H-NMR (d₆-DMSO) δ 0.85 (3H, t), 1.22 (18H, m), 1.35-1.61 (2H, m), 2.78, 2.95 (3H, 2xs), 3.20-3.35 (2H, m), 3.58 (2H, s), 4.40 (2H, s), 4.55 (2H, s), 4.83 (2H, m), 7.10 (2H, m), 7.44 (2H, m), 7.54 and 7.57 (1H, 2xs), 8.03 (1H, m), 8.54 (1H, m) 13.10 (1H, br. s); MS (APCI+) found (M+1) = 642, C₃₃H₄₄FN₅O₅S requires 641.


Example 17 - 1-(N-(1-Octyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-(methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



Prepared analogously to example 3.

¹H-NMR (CDCl₃) δ 0.8-0.95 (3H,t), 1.1-1.8 (12H,m), 2.73 (3H,bs), 2.93 and 3.00 (3H,2xs), 3.15-3.7 (4H,s), 4.68 (2H,bs), 4.79 (2H, bd), 6.85-7.1 (2H, m), 7.2-7.5 (3H,m), 7.71 (1H,m), 8.63 (1H,bs), 8.82(1H,bs); MS (APCI+) found (M+1) = 599; C₃₀H₃₉FN₆O₄S requires 598.


Example 18 - 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)-thio-5-(1-(methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one



Prepared analogously to example 3.

¹H-NMR (d₆-DMSO) δ 0.8-0.95 (3H,m), 1.05-1.7 (20H,m), 2.60 and 2.62 (3H,2xs), 2.81 and 2.95 (3H,2xs), 3.2-3.55 (4H,m), 4.39 (2H,s), 4.45 (2H,s), 4.84 (2H,bd), 7.05-7.2 (2H,m), 7.35-7.6 (3H,m), 7.98 (1H,d), 8.1-8.25 (1H,m), 8.51 (1H,d); MS (APCI+) found (M+1) = 655; C₃₄H₄₇FN₆O₄S requires 654.

Example 19 - 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)-thio-5-(1-(1-morpholinocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one




Prepared analogously to example 3.

$^1\text{H-NMR}$ (CDCl_3) δ 0.8-0.95 (3H,m), 1.05-1.75 (20H,m), 2.6-3.9 (15H,m), 4.45 (2H,bs), 4.55-4.9 (4H,m), 6.85-7.05 (2H,m), 7.1-7.4 (3H,m), 7.87 (1H,bs), 8.47 (1H,s); MS

5 (APCI+) found $(\text{M}+1) = 711$; $\text{C}_{37}\text{H}_{51}\text{FN}_6\text{O}_5\text{S}$ requires 710.

Example 20 - 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)-thio-5-(1-carboxymethyl-2-oxopyrimidin-5-ylmethyl)pyrimidin-4-one – sodium salt




- 10 The acid of Example 16 (4.91g) was added to a solution/suspension of sodium bicarbonate (0.64g) in water (60ml). The mixture was stirred at room temperature for 5 min and at 50°C for 5 min. After sonication for 8 min at room temperature, further water (100ml) was added and the undissolved material broken up. The mixture was heated and stirred for a further 5 min at 50°C and sonicated for a further 8 min at room temperature.
- 15 Any remaining solid was filtered off and washed with water. The clear filtrate was freeze-dried for 16h to give the sodium salt. $^1\text{H-NMR}$ ($\text{d}_6\text{-DMSO}$) δ 0.85 (3H,t), 1.1–1.65 (20H,m), 2.81 and 2.94 (3H,2xs), 3.2-3.4 (4H,m), 4.09 (2H,s), 4.40 (2H,s), 4.84 and 4.85 (2H,2xs), 7.05-7.2 (2H,m), 7.4-7.55 (3H,m), 7.87(1H,m), 8.38 (2H,m); MS (ES) found $(\text{M}+1)$ (free acid)=642; $\text{C}_{33}\text{H}_{44}\text{FN}_5\text{O}_4\text{S}$ requires 642.

Biological Data

1. Screen for Lp-PLA₂ inhibition.

- 5 Enzyme activity was determined by measuring the rate of turnover of the artificial substrate (A) at 37 °C in 50mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid) buffer containing 150mM NaCl, pH 7.4.



10

(A)

Assays were performed in 96 well titre plates.

- 15 Recombinant LpPLA₂ was purified to homogeneity from baculovirus infected Sf9 cells, using a zinc chelating column, blue sepharose affinity chromatography and an anion exchange column. Following purification and ultrafiltration, the enzyme was stored at 6mg/ml at 4°C. Assay plates of compound or vehicle plus buffer were set up using automated robotics to a volume of 170µl. The reaction was initiated by the addition of 20µl of 10x substrate (A) to give a final substrate concentration of 20µM and 10 µl of diluted enzyme to a final 0.2nM LpPLA₂.

20

The reaction was followed at 405 nm and 37 °C for 20 minutes using a plate reader with automatic mixing. The rate of reaction was measured as the rate of change of absorbance.


Results

25

The compounds described in Examples 1 to 19 were tested as described above and had respective IC₅₀ values of in the range 0.0004 to 3.2 µM.

Claims

1. A compound of formula (I):



(I)

in which:

R^1 is COOH or a salt thereof, COOR¹⁰, CONR¹¹R¹², CN or CH₂OH;

10 R^2 is a mono- or bicyclic aromatic ring system containing up to 10 carbon atoms in the ring system, or a mono- or bicyclic heteroaromatic ring system including up to 4 heteroatoms selected from N, O and S; optionally substituted by 1, 2, 3 or 4 substituents selected from C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkylthio, aryl, aralkyl, hydroxy, oxo, halogen, CN, COOH or a salt thereof, COO-C₁₋₆alkyl, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, SO₂NR¹⁵R¹⁶,
15 NR¹⁵SO₂R¹⁶, NR¹⁵R¹⁶, mono to perfluoro C₁₋₄alkyl and mono to perfluoro C₁₋₄alkoxy;

R^3 is C₁₋₂₀ alkyl, C₃₋₆ cycloalkyl, C₃₋₆cycloalkylC₁₋₅alkyl, or C₁₋₁₀ alkoxyC₁₋₁₀ alkyl, each optionally substituted by 1 or 2 substituents selected from hydroxy, C₁₋₁₀ alkoxy, COOH or a salt thereof, COOC₁₋₁₅ alkyl, CONR¹⁷R¹⁸, NR¹⁷R¹⁸, NR¹⁷COR¹⁸, NR¹⁹ or an aromatic or heteroaromatic ring system as defined for

20 R^2 , or R^3 is an aromatic or heteroaromatic ring system as hereinbefore defined for R^2 ;

R^{10} is C₁₋₄alkyl or a pharmaceutically acceptable *in vivo* hydrolysable ester group;

R^{11} and R^{12} which may be the same or different is each selected from hydrogen, C₁₋₁₂alkyl, CH₂R¹³, CHR¹⁴CO₂H or a salt thereof, or R^{11} and R^{12} together with the
25 nitrogen to which they are attached form a 5- to 7 membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C₁₋₄alkyl, C₁₋₄alkylCO, aryl, or aralkyl;

R^{13} is COOH or a salt thereof, COOR¹⁰, CONR¹¹R¹², CN or CH₂OH;

30 R^{14} is an amino acid side chain such as CH₂OH from serine;

R^{15} and R^{16} are independently hydrogen or C₁₋₄ alkyl e.g. methyl or ethyl;

R¹⁷ and R¹⁸ are independently hydrogen, C₁₋₁₅ alkyl, eg methyl or ethyl, C₁₋₁₀ alkoxyC₁₋₁₀ alkyl or arylC₁₋₁₀ alkyl, e.g. benzyl;

R¹⁹ together with the nitrogen atom to which it is attached forms a 5- to 7 membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C₁₋₄ alkyl, aryl, e.g. phenyl, or aralkyl, e.g. benzyl;

W is SO₂ or a bond;

X is O or S; and

Y is a group of the formula -A¹-A²-A³- in which A¹ and A³ each represent a bond or a straight chain or branched alkylene group, said alkylene group(s) containing a total of 1 to 10 carbon atoms and A² represents a bond or O, S, SO, SO₂, CO, C=CH₂, CONH, NHCO, CR¹⁵R¹⁶, CH=CH or C≡C, providing that when A² is O, S, SO, SO₂ or CONH, A³ contains at least two carbon atoms linking the A² group and the CH₂ group in formula (I).

15

2. A compound as claimed in claim 1 in which Y is S.

3. A compound as claimed in claim 1 or 2 in which W is a bond.

20 4. A compound as claimed in any one of claims 1 to 3 in which R² is a phenyl ring, optionally substituted by 4-fluoro.

5. A compound as claimed in any one of claims 1 to 4 in which R³ is C₁₋₂₀ alkyl or R¹⁷R¹⁸NHCOCH₂- in which R¹⁷ and R¹⁸ is each independently C₁₋₁₅ alkyl.

25

6. A compound as claimed in any one of claims 1 to 5 in which R¹ is instance a sodium salt, an ethyl ester, an N-alkyl or di- N-alkyl amide, or an amide in which the N forms part of a heterocyclic ring.

30 7. A compound of formula (I) as defined in claim 1 selected from:

1-(1-Undecyl)-2-(4-fluorobenzyl)thio-5-(1-(ethoxycarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;


1-(1-Undecyl)-2-(4-fluorobenzyl)thio-5-(1-(carboxymethyl)-2-oxopyrimid-5-ylmethyl)-pyrimidin-4-one;

35 1-(1-Undecyl)-2-(4-fluorobenzyl)thio-5-(1-(dimethylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;

1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(ethoxycarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;

- 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(carboxymethyl)-2-oxopyrimid-5-ylmethyl)-pyrimidin-4-one;
 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(1-octylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 5 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-benzyl-N-methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-(1-dodecyl)-N-methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-(2-methoxyethyl)-N-methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 10 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(4-hydroxy-4-benzylpiperidin-1-ylcarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 1-Methyl-2-(4-fluorobenzyl)thio-5-(1-(N-(1-octyl)-N-methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 15 1-(N-(1-Octyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-ethoxycarbonylmethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 1-(N-(1-Octyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-carboxymethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-ethoxycarbonylmethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 20 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-carboxymethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 1-(N-(1-Octyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-(methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 25 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-(methylaminocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one;
 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-(1-morpholinocarbonylmethyl)-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one; and
 30 1-(N-(1-Dodecyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-carboxymethyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4-one – sodium salt.

8. A process for the preparation of compounds of formula (I) as defined in claim 1 which comprises reacting a compound of formula (II):



35

(II)

- in which R^2 , R^3 , W, X and Y are as defined in claim 1;
with an alkylating agent of formula $R^{10}-CH_2-L^1$ in which R^{10} is as hereinbefore defined
and L^1 is a leaving group such as chlorine, bromine, iodine or mesylate, in the presence
of a base such as potassium carbonate; and thereafter, and if necessary,
- 5 interconverting Z groups, for example $COOR^{10}$ to $COOH$ by standard conditions
(alkaline hydrolysis, hydrogenation of benzyl ester, etc), or $COOH$ to $CONR^{11}R^{12}$ by
amide coupling.
9. A pharmaceutical composition comprising a compound of formula (I) as defined in
10 claim and a pharmaceutically acceptable carrier.
10. A compound of formula (I) as defined in claim 1 for use in therapy.
11. A compound of formula (I) as claimed in claim 1 for use in the treatment of
15 atherosclerosis.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/06093

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/56 C07D401/14 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 154 834 A (BROWN THOMAS H ET AL) 15 May 1979 (1979-05-15) the whole document ---	1-11
A	US 4 145 546 A (BROWN THOMAS H ET AL) 20 March 1979 (1979-03-20) the whole document ---	1-11
P,A	WO 99 24420 A (SMITH STEPHEN ALLAN ; IFE ROBERT JOHN (GB); PINTO IVAN LEO (GB); HI) 20 May 1999 (1999-05-20) cited in the application claims -----	1-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 December 1999

Date of mailing of the international search report

19/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/06093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4154834 A	15-05-1979	US 4216318 A	05-08-1980
		AR 222290 A	15-05-1981
		AT 360024 B	10-12-1980
		AT 960876 A	15-05-1980
		AU 508123 B	13-03-1980
		AU 2097676 A	06-07-1978
		BE 849810 A	23-06-1977
		BG 29722 A	15-01-1981
		CA 1073458 A	11-03-1980
		CH 631981 A	15-09-1982
		CS 203995 B	31-03-1981
		CY 1244 A	29-06-1984
		DD 128588 A	30-11-1977
		DE 2658267 A	07-07-1977
		DK 587076 A	30-06-1977
		EG 12439 A	30-09-1979
		ES 454656 A	16-11-1977
		FI 763664 A, B,	30-06-1977
		FR 2336935 A	29-07-1977
		GB 1582527 A	07-01-1981
		GR 62441 A	12-04-1979
		HK 76084 A	12-10-1984
		HU 175171 B	28-05-1980
		IE 45082 B	16-06-1982
		IL 51040 A	31-12-1980
		IT 1124740 B	14-05-1986
		JP 52083388 A	12-07-1977
		JP 61029355 B	05-07-1986
		KE 3388 A	25-05-1984
		LU 76481 A	15-06-1977
		MW 5076 A	08-02-1978
		MX 5119 E	24-03-1983
		MY 37585 A	31-12-1985
		NL 7614538 A	01-07-1977
		NO 764370 A, B,	30-06-1977
		NZ 182759 A	02-06-1978
		OA 5526 A	30-04-1981
		PH 14723 A	13-11-1981
		PT 65949 A, B	01-01-1977
		RO 72475 A	26-10-1982
		SE 431544 B	13-02-1984
		SE 7614620 A	30-06-1977
		SG 13084 G	15-02-1985
		YU 311676 A	21-01-1983
		ZA 7607198 A	30-11-1977
		ZM 14376 A	22-08-1977
US 4145546 A	20-03-1979	AR 221682 A	13-03-1981
		AT 358045 B	11-08-1980
		AT 711976 A	15-01-1980
		AU 504897 B	01-11-1979
		AU 1829576 A	06-04-1978
		BE 846452 A	22-03-1977
		BG 25224 A	10-08-1978
		CA 1067076 A	27-11-1979
		CH 625801 A	15-10-1981
		CS 203003 B	27-02-1981
		DD 126563 A	27-07-1977

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/06093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4145546 A		DE 2643670 A	14-04-1977
		DK 442476 A	03-04-1977
		ES 452060 A	01-10-1977
		FI 762803 A,B,	03-04-1977
		FR 2326192 A	29-04-1977
		GR 61307 A	19-10-1978
		HU 175537 B	28-08-1980
		IE 44845 B	21-04-1982
		IL 50503 A	31-12-1980
		IN 146736 A	25-08-1979
		IT 1070839 B	02-04-1985
		JP 52046087 A	12-04-1977
		JP 56035674 B	19-08-1981
		JP 1287509 C	31-10-1985
		JP 56095186 A	01-08-1981
		JP 60009755 B	12-03-1985
		LU 75922 A	06-05-1977
		MW 3476 A	09-11-1977
		MX 4614 E	07-07-1982
		NL 7609917 A	05-04-1977
		NO 763371 A,B,	05-04-1977
		NZ 181959 A	28-07-1978
		OA 5445 A	31-03-1981
		PH 13921 A	04-11-1980
		PT 65590 A,B	01-10-1976
		RO 73511 A	30-04-1981
		SE 431872 B	05-03-1984
		SE 7610409 A	03-04-1977
		US 4159329 A	26-06-1979
		US 4218452 A	19-08-1980
		YU 237276 A	21-01-1983
		ZA 7605498 A	31-08-1977
		ZM 12176 A	21-07-1977
WO 9924420 A	20-05-1999	AU 1157599 A	31-05-1999